Leap Therapeutics Inc. (LPTX) has several pivotal clinical trial milestones to watch for in the coming months, particularly regarding its lead drug candidate, DKN-01, an anti-DKK1 monoclonal antibody.
DKN-01 is being tested in combination with standard therapies for advanced colorectal and gastric cancers. A phase II trial evaluating DKN-01 in combination with bevacizumab and chemotherapy for second-line treatment of advanced colorectal cancer, dubbed DeFianCe, is underway. Enrollment in the expanded randomized controlled Part B of the DeFianCe study has been completed, with initial results expected in mid-2025.
For comments and feedback contact: editorial@rttnews.com
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.